Selecting the Right Biologic for Your Patients with Severe Asthma

Severe asthma affects 5-10% of the adult asthma population and is associated with increased morbidity, mortality, and consumption of health care resources. Recently, several biologic medications have been approved for use in severe asthma. These medications target the type-2 inflammatory pathway, which is characterized by activation of cytokines including interleukin (IL)-4, IL-5 and IL-13, which results in eosinophilia, high fractional exhaled nitric oxide (FeNO) and atopic features. The objective of this review is to provide clinicians with key points to assist in selecting the best biologic medication for each patient.

https://ift.tt/2K0e47H